These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11367984)

  • 1. [Effect of celecoxib, a COX-2 inhibitor, in familial adenomatous polyposis].
    Wullen B; Mühlhöfer A; Zoller WG
    Z Gastroenterol; 2001 Apr; 39(4):335-7. PubMed ID: 11367984
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
    Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
    N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention comes to clinical practice: COX-2 inhibition in familial adenomatous polyposis.
    Bresalier RS
    Gastroenterology; 2000 Dec; 119(6):1797-8. PubMed ID: 11113106
    [No Abstract]   [Full Text] [Related]  

  • 4. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
    Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arthritis drug approved for polyp prevention blazes trail for other prevention trials.
    Smigel K
    J Natl Cancer Inst; 2000 Feb; 92(4):297-9. PubMed ID: 10675374
    [No Abstract]   [Full Text] [Related]  

  • 6. Celecoxib: a new option in the treatment of arthropathies and familial adenomatous polyposis.
    Davies NM; Gudde TW; de Leeuw MA
    Expert Opin Pharmacother; 2001 Jan; 2(1):139-52. PubMed ID: 11336575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pain management in patients with osteoarthritis.
    Finucane TE
    JAMA; 2003 Jul; 290(1):36; author reply 36. PubMed ID: 12837705
    [No Abstract]   [Full Text] [Related]  

  • 8. [Improper use of selective COX-2 inhibitor NSAIDs].
    Rocamora Batalla M; Vallano Ferraz A
    Aten Primaria; 2002 Feb; 29(2):122. PubMed ID: 11844430
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclooxygenase inhibition in cancer--a blind alley or a new therapeutic reality?
    Chau I; Cunningham D
    N Engl J Med; 2002 Apr; 346(14):1085-7. PubMed ID: 11932478
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular events and COX-2 inhibitors.
    Fleming M
    JAMA; 2001 Dec; 286(22):2808; author reply 2811-2. PubMed ID: 11735742
    [No Abstract]   [Full Text] [Related]  

  • 11. COX-2 inhibitors. Magic bullets or merely mortal?
    Harv Health Lett; 2000 Feb; 25(4):4. PubMed ID: 10637015
    [No Abstract]   [Full Text] [Related]  

  • 12. Visual disturbance associated with celecoxib.
    Lund BC; Neiman RF
    Pharmacotherapy; 2001 Jan; 21(1):114-5. PubMed ID: 11191731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
    Fernandez H; Lesser GT
    JAMA; 2000 Apr; 283(15):1961; author reply 1962. PubMed ID: 10789661
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclooxygenase 2 selective agents and upper gastrointestinal disease.
    Palmer RH
    JAMA; 2000 Apr; 283(15):1961-2. PubMed ID: 10789662
    [No Abstract]   [Full Text] [Related]  

  • 15. [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
    MMW Fortschr Med; 2003 May; 145(18):54. PubMed ID: 12808824
    [No Abstract]   [Full Text] [Related]  

  • 16. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 17. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
    Hrachovec JB; Mora M
    JAMA; 2001 Nov; 286(19):2398; author reply 2399-400. PubMed ID: 11712924
    [No Abstract]   [Full Text] [Related]  

  • 18. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib.
    Wright JM; Perry TL; Bassett KL; Chambers GK
    JAMA; 2001 Nov; 286(19):2398-400. PubMed ID: 11712925
    [No Abstract]   [Full Text] [Related]  

  • 19. Celecoxib: a COX-2 inhibitor.
    Andrews SA; Wallace CK; Davis RL
    Am J Manag Care; 1999 Apr; 5(4):511-8; quiz 522-4. PubMed ID: 10387389
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
    Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.